Related Experiment Videos

[Comparative evaluation of the antihypertensive efficacy of amlodipine versus enalapril]

Fredi Alicajić1

  • 1Dom Zdravlja Cazin, Bosna i Hercegovina.

Medicinski Arhiv
|May 8, 2009
PubMed

Insights

Amlodipine and enalapril effectively treated moderate essential hypertension in patients. Amlodipine demonstrated slightly greater blood pressure reduction compared to enalapril, with both medications proving safe and well-tolerated.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Essential hypertension is a prevalent cardiovascular condition requiring effective management.
  • Calcium channel blockers and ACE inhibitors are common therapeutic classes for hypertension.

Purpose of the Study:

  • To compare the efficacy and safety of amlodipine versus enalapril in patients with moderate essential hypertension.
  • To evaluate blood pressure reduction and side effect profiles of both drugs.

Main Methods:

  • A randomized study involving 40 patients with moderate essential hypertension (diastolic BP 100-120 mmHg).
  • Patients received either amlodipine (5-10 mg daily) or enalapril (5-10 mg daily) for four weeks after a two-week washout period.
  • Blood pressure was monitored before and after treatment.

Main Results:

  • Both amlodipine and enalapril significantly reduced blood pressure.
  • Amlodipine lowered mean BP from 173.00/108.00 to 129.75/78.50 mmHg.
  • Enalapril lowered mean BP from 175.25/106.75 to 133.50/81.50 mmHg.
  • No significant side effects were reported in either treatment group.
  • Amlodipine showed a slightly greater reduction in blood pressure compared to enalapril.

Conclusions:

  • Low-dose amlodipine (5-10 mg daily) and enalapril are efficient and safe treatment options for essential hypertension.
  • Amlodipine may offer a marginally superior blood pressure-lowering effect compared to enalapril in this patient population.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...